Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 83

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 83
---
otherapy in checkpoint inhibitor non-responsive tumor types and patients.
 
Given a growing body of literature, it is becoming increasingly clear that modulation of the gut microbiota may represent a novel and important adjunct to current anti-cancer therapeutic modalities.
 
GI related disorders
 

◾                             Irritable Bowel Syndrome (IBS) is a common disorder that affects the large intestine.                           
    Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. It is estimated that the global
      irritable bowel syndrome treatment market accounted for $ 1.65 billion in 2023 and is expected to reach at $4.74 billion by 2034 with   
        a CAGR of 10.07% during the forecast period 2024-2034 according to a report titled the “Irritable Bowel Syndrome Treatment Market     
                                          by Type, by Product, by Distribution Channel, and by Region”7,                                      
    which is not incorporated herein by reference. Existing drugs for IBS mainly treat the symptoms of the condition, leaving patients exposed
                                   to cycles of remission and relapse that characterize this chronic condition.                               
----------------------------------------------------------------------------------------------------------------------------------------------

◾                            IBD is a group of GI diseases, mainly comprised of Ulcerative colitis and Crohn’s disease.                        
    IBDs cause long term chronic as well as severe inflammation in the gastrointestinal tract without any known cause. According to the Centers
      for Disease Control and Prevention, or CDC, in 2015 an estimated 3.1 million people (1.3% of the entire population) in the United States 
         were diagnosed either with Crohn’s disease or with Ulcerative Colitis. According to a report published by Research and Markets in     
       January 2024, which is not incorporated by reference herein, the global IBD drug market size was valued at $26.65 billion in 2023, and  
           is projected to reach $49.76 billion by 2034, growing at a compound annual growth rate, or CAGR, of 5.84% from 2023 to 20348.       
-----------------------------------------------------------------------------------------------------------------------------------------------

                                                                                                                    ________________________                                                                                                                    
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           6 https://www.biospace.com/cancer-immunotherapy-market-size-to-hit-usd-296-01-billion-by-2033#:~:text=The%20U.S.%20cancer%20immunotherapy%20market,8